Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka 020-8505, Japan.
Cancer Chemother Pharmacol. 2013 Mar;71(3):657-62. doi: 10.1007/s00280-012-2052-2. Epub 2012 Dec 23.
There are no reports on the use of neoadjuvant chemotherapy (NAC) in non-squamous cell cervical carcinoma. We examined the effectiveness and safety of paclitaxel/carboplatin (TC) and docetaxel/carboplatin (DC).
Stage Ib2 to IIb disease was present in 23 patients scheduled for radical hysterectomy. We administered 1-3 courses of either the TC or the DC regimen. Anti-tumor effects were found superior by Response Evaluation Criteria in Solid Tumors. Safety was assessed with National Cancer Institute Common Terminology Criteria for Adverse Events.
Median age was 50 years (range 32-63 years), with stage Ib2 in 6 cases (26.1%) and IIb in 17 cases (73.9%). Complete response was achieved in 5 cases (21.7%), partial response in 13 (56.5%), stable disease in 5 (21.7%); the response rate was 78.3%, and surgery completion rate was 78.3%. Leukopenia or neutropenia ≥grade 3 was seen in 12 (52.2%) and 21 (91.3%) cases, respectively, with grade 3 febrile neutropenia in 2 cases (8.7%) and no anemia or thrombocytopenia ≥grade 3. Median progression-free survival was 26 months (95% Cl, 13.5-38.5 months); median overall survival was 35 months (95% Cl, 20.9-49.1 months).
NAC for non-squamous cell cervical carcinoma showed potent anti-tumor effects and manageable adverse events.
尚无新辅助化疗（NAC）治疗非鳞宫颈癌的报道。我们研究了紫杉醇/卡铂（TC）和多西他赛/卡铂（DC）的疗效和安全性。
23 例拟行根治性子宫切除术的患者存在 Ib2 期至 IIb 期疾病。我们给予 1-3 个疗程 TC 或 DC 方案。采用实体瘤反应评价标准（RECIST）评估抗肿瘤效果，采用国立癌症研究所不良事件通用术语标准（NCI CTCAE）评估安全性。
中位年龄为 50 岁（范围 32-63 岁），Ib2 期 6 例（26.1%），IIb 期 17 例（73.9%）。完全缓解 5 例（21.7%），部分缓解 13 例（56.5%），稳定 5 例（21.7%）；总缓解率为 78.3%，手术完成率为 78.3%。白细胞减少或中性粒细胞减少≥3 级分别为 12 例（52.2%）和 21 例（91.3%），其中 3 级发热性中性粒细胞减少 2 例（8.7%），无贫血或血小板减少≥3 级。无进展生存中位数为 26 个月（95%CI，13.5-38.5 个月）；总生存中位数为 35 个月（95%CI，20.9-49.1 个月）。
NAC 治疗非鳞宫颈癌显示出较强的抗肿瘤作用和可管理的不良反应。
